Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2023 08:00 ET | Source: BioVie, Inc.

BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023

CARSON CITY, Nev., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
October 25, 2023 12:30 ET | Source: BioVie, Inc.

Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients

Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS,...
October 19, 2023 07:30 ET | Source: BioVie, Inc.

BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD

CARSON CITY, Nev., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
September 26, 2023 08:00 ET | Source: BioVie, Inc.

BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

Expects to announce topline data expected in the November/December timeframe.Enrolled patients had underlying medical conditions that are known risk factors for dementia that NE3107 has the potential...
September 19, 2023 08:00 ET | Source: BioVie, Inc.

BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference

CARSON CITY, Nev., Sept. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
September 11, 2023 08:00 ET | Source: BioVie, Inc.

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

Data from Phase 3 Trial of NE3107 Presented as Poster at the 148th American Neurological Association Annual Meeting CARSON CITY, Nev., Sept. 11, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI)...
September 07, 2023 08:00 ET | Source: BioVie, Inc.

BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023

CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
August 31, 2023 08:00 ET | Source: BioVie, Inc.

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023

CARSON CITY, Nev., Aug. 31, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
August 28, 2023 08:00 ET | Source: BioVie, Inc.

BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders

New preclinical data characterizing NE3107 mechanism of action featured in oral presentationPhamacokinetic data from Phase 2a study supports potential co-administration of NE3107 with...
July 18, 2023 07:00 ET | Source: BioVie, Inc.

BioVie Issues Letter to Shareholders

Treatment with NE3107 led to >50% reductions in DNA methylation of 400 CpGs1 and some in a manner that was significantly correlated to observed clinical improvements in cognition and various...